Ezetimibe as a potential treatment for non alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation?
Ahmed, Mohamed H. and Byrne, Christopher D. (2010) Ezetimibe as a potential treatment for non alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation? Drug Discovery Today, 15, (15-16), 590-595. (doi:10.1016/j.drudis.2010.06.007). (PMID:20601094).
- Author's Original
Restricted to System admin
Non-alcoholic fatty liver disease (NAFLD) is the hepatic component of the metabolic syndrome and is known to be associated with significant insulin resistance and increased risk of cardiovascular disease. .Ezetimibe, an inhibitor of intestinal cholesterol absorption, has been shown to inhibit Niemann-Pick C1-like 1 (NPC1L1) . Interestingly, NPC1L1 is abundantly expressed in human liver as well as in the intestine. Recent reports suggest a potential benefit of ezetimibe in improving hepatic insulin sensitivity and decreasing hepatic inflammation and lipid accumulation. The presence of insulin resistance and excess hepatic fat accumulation are regarded as key factors in the pathogenesis of NAFLD. Therefore, we suggest that urgent studies are needed to assess the potential therapeutic benefit of ezetimibe in treating NAFLD.
|Digital Object Identifier (DOI):||doi:10.1016/j.drudis.2010.06.007|
|Subjects:||R Medicine > RB Pathology
R Medicine > RS Pharmacy and materia medica
R Medicine > RM Therapeutics. Pharmacology
|Divisions:||University Structure - Pre August 2011 > School of Medicine > Developmental Origins of Health and Disease
|Date Deposited:||16 Jun 2010 13:38|
|Last Modified:||31 Mar 2016 13:27|
|RDF:||RDF+N-Triples, RDF+N3, RDF+XML, Browse.|
Actions (login required)